Clinical Pharmacokinetics of Lofexidine, the [alpha] 2-Adrenergic Receptor Agonist, in Opiate Addicts Plasma Using a Highly Sensitive Liquid Chromatography Tandem Mass Spectrometric Analysis

The objective of this investigation was to characterize the pharmacokinetic profile of lofexidine. Lofexidine is an orally bioavailable α 2-adrenergic receptor agonist analogue of clonidine that acts centrally to suppress opiate withdrawal symptoms. During the detoxification period of a phase 3 plac...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of drug and alcohol abuse 2008-09, Vol.34 (5), p.611
Main Authors: Yu, Elmer, Miotto, Karen, Akerele, Evaristo, O'Brien, Charles P, Ling, Walter, Kleber, Herbert, Fischman, Marian W, Elkashef, Ahmed, Herman, Barbara H, Al-Ghananeem, Abeer M
Format: Article
Language:English
Subjects:
Chromatography
Drug abuse
Drug addiction
Drugs
Mass spectrometry
Medical research
Narcotics
Pharmacology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 5
container_start_page 611
container_title The American journal of drug and alcohol abuse
container_volume 34
creator Yu, Elmer
Miotto, Karen
Akerele, Evaristo
O'Brien, Charles P
Ling, Walter
Kleber, Herbert
Fischman, Marian W
Elkashef, Ahmed
Herman, Barbara H
Al-Ghananeem, Abeer M
description The objective of this investigation was to characterize the pharmacokinetic profile of lofexidine. Lofexidine is an orally bioavailable α 2-adrenergic receptor agonist analogue of clonidine that acts centrally to suppress opiate withdrawal symptoms. During the detoxification period of a phase 3 placebo-controlled, randomized, double-blind trial, six subjects were entered in this preliminary pharmacokinetic study. Pharmacokinetic analysis of plasma samples collected during study day 7 indicated that C... was 3242 ± 917 ng/L. The mean trough levels between the study days were not significantly different (p > .05), suggesting that the subjects were at steady-state. Although preliminary due to the limited number of subjects, these findings are the first to document lofexidine clinical pharmacokinetics in opiate addicts using a highly sensitive liquid chromatography tandem mass spectrometric analysis. (ProQuest: ... denotes formulae/symbols omitted.)
doi_str_mv 10.1080/00952990802308122
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_219345657</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1589444861</sourcerecordid><originalsourceid>FETCH-proquest_journals_2193456573</originalsourceid><addsrcrecordid>eNqNjc1Kw0AUhQdRsP48gLuL60YnSWszy1CULioWW1ci5ZLcJrcmM-ncqdiX89lMwQdwdQ7n--AodRPru1hn-l5rM06M6WuS6ixOkhM1iLWZRCYz8akaHHl0FM7VhchWax1nk9FA_UwbtlxgA4safYuF-2RLgQsBt4G529A3l_0yhFATvGPT1fgBSZSXniz5igt4pYK64DzklbMsYQhs4aVjDAR5WXIRBBYNSovwJmwrQJhxVTcHWJIVDvxFMOfdnkuY1t61GFzlsasPsEJbUgvPKALLjorQUwq-_8wtNgdhuVJnG2yErv_yUt0-Pa6ms6jzbrcnCeut2_telnUSm3Q0fhhP0n9JvwFQbTQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219345657</pqid></control><display><type>article</type><title>Clinical Pharmacokinetics of Lofexidine, the [alpha] 2-Adrenergic Receptor Agonist, in Opiate Addicts Plasma Using a Highly Sensitive Liquid Chromatography Tandem Mass Spectrometric Analysis</title><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><source>Sociological Abstracts</source><source>SPORTDiscus with Full Text</source><creator>Yu, Elmer ; Miotto, Karen ; Akerele, Evaristo ; O'Brien, Charles P ; Ling, Walter ; Kleber, Herbert ; Fischman, Marian W ; Elkashef, Ahmed ; Herman, Barbara H ; Al-Ghananeem, Abeer M</creator><creatorcontrib>Yu, Elmer ; Miotto, Karen ; Akerele, Evaristo ; O'Brien, Charles P ; Ling, Walter ; Kleber, Herbert ; Fischman, Marian W ; Elkashef, Ahmed ; Herman, Barbara H ; Al-Ghananeem, Abeer M</creatorcontrib><description>The objective of this investigation was to characterize the pharmacokinetic profile of lofexidine. Lofexidine is an orally bioavailable α 2-adrenergic receptor agonist analogue of clonidine that acts centrally to suppress opiate withdrawal symptoms. During the detoxification period of a phase 3 placebo-controlled, randomized, double-blind trial, six subjects were entered in this preliminary pharmacokinetic study. Pharmacokinetic analysis of plasma samples collected during study day 7 indicated that C... was 3242 ± 917 ng/L. The mean trough levels between the study days were not significantly different (p &gt; .05), suggesting that the subjects were at steady-state. Although preliminary due to the limited number of subjects, these findings are the first to document lofexidine clinical pharmacokinetics in opiate addicts using a highly sensitive liquid chromatography tandem mass spectrometric analysis. (ProQuest: ... denotes formulae/symbols omitted.)</description><identifier>ISSN: 0095-2990</identifier><identifier>EISSN: 1097-9891</identifier><identifier>DOI: 10.1080/00952990802308122</identifier><identifier>CODEN: AJDABD</identifier><language>eng</language><publisher>New York: Taylor &amp; Francis Ltd</publisher><subject>Chromatography ; Drug abuse ; Drug addiction ; Drugs ; Mass spectrometry ; Medical research ; Narcotics ; Pharmacology</subject><ispartof>The American journal of drug and alcohol abuse, 2008-09, Vol.34 (5), p.611</ispartof><rights>Copyright Marcel Dekker, Inc. Sep 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908,30982,33757</link.rule.ids></links><search><creatorcontrib>Yu, Elmer</creatorcontrib><creatorcontrib>Miotto, Karen</creatorcontrib><creatorcontrib>Akerele, Evaristo</creatorcontrib><creatorcontrib>O'Brien, Charles P</creatorcontrib><creatorcontrib>Ling, Walter</creatorcontrib><creatorcontrib>Kleber, Herbert</creatorcontrib><creatorcontrib>Fischman, Marian W</creatorcontrib><creatorcontrib>Elkashef, Ahmed</creatorcontrib><creatorcontrib>Herman, Barbara H</creatorcontrib><creatorcontrib>Al-Ghananeem, Abeer M</creatorcontrib><title>Clinical Pharmacokinetics of Lofexidine, the [alpha] 2-Adrenergic Receptor Agonist, in Opiate Addicts Plasma Using a Highly Sensitive Liquid Chromatography Tandem Mass Spectrometric Analysis</title><title>The American journal of drug and alcohol abuse</title><description>The objective of this investigation was to characterize the pharmacokinetic profile of lofexidine. Lofexidine is an orally bioavailable α 2-adrenergic receptor agonist analogue of clonidine that acts centrally to suppress opiate withdrawal symptoms. During the detoxification period of a phase 3 placebo-controlled, randomized, double-blind trial, six subjects were entered in this preliminary pharmacokinetic study. Pharmacokinetic analysis of plasma samples collected during study day 7 indicated that C... was 3242 ± 917 ng/L. The mean trough levels between the study days were not significantly different (p &gt; .05), suggesting that the subjects were at steady-state. Although preliminary due to the limited number of subjects, these findings are the first to document lofexidine clinical pharmacokinetics in opiate addicts using a highly sensitive liquid chromatography tandem mass spectrometric analysis. (ProQuest: ... denotes formulae/symbols omitted.)</description><subject>Chromatography</subject><subject>Drug abuse</subject><subject>Drug addiction</subject><subject>Drugs</subject><subject>Mass spectrometry</subject><subject>Medical research</subject><subject>Narcotics</subject><subject>Pharmacology</subject><issn>0095-2990</issn><issn>1097-9891</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><sourceid>BHHNA</sourceid><recordid>eNqNjc1Kw0AUhQdRsP48gLuL60YnSWszy1CULioWW1ci5ZLcJrcmM-ncqdiX89lMwQdwdQ7n--AodRPru1hn-l5rM06M6WuS6ixOkhM1iLWZRCYz8akaHHl0FM7VhchWax1nk9FA_UwbtlxgA4safYuF-2RLgQsBt4G529A3l_0yhFATvGPT1fgBSZSXniz5igt4pYK64DzklbMsYQhs4aVjDAR5WXIRBBYNSovwJmwrQJhxVTcHWJIVDvxFMOfdnkuY1t61GFzlsasPsEJbUgvPKALLjorQUwq-_8wtNgdhuVJnG2yErv_yUt0-Pa6ms6jzbrcnCeut2_telnUSm3Q0fhhP0n9JvwFQbTQ</recordid><startdate>20080901</startdate><enddate>20080901</enddate><creator>Yu, Elmer</creator><creator>Miotto, Karen</creator><creator>Akerele, Evaristo</creator><creator>O'Brien, Charles P</creator><creator>Ling, Walter</creator><creator>Kleber, Herbert</creator><creator>Fischman, Marian W</creator><creator>Elkashef, Ahmed</creator><creator>Herman, Barbara H</creator><creator>Al-Ghananeem, Abeer M</creator><general>Taylor &amp; Francis Ltd</general><scope>7QJ</scope><scope>7U3</scope><scope>BHHNA</scope><scope>K7.</scope><scope>K9.</scope></search><sort><creationdate>20080901</creationdate><title>Clinical Pharmacokinetics of Lofexidine, the [alpha] 2-Adrenergic Receptor Agonist, in Opiate Addicts Plasma Using a Highly Sensitive Liquid Chromatography Tandem Mass Spectrometric Analysis</title><author>Yu, Elmer ; Miotto, Karen ; Akerele, Evaristo ; O'Brien, Charles P ; Ling, Walter ; Kleber, Herbert ; Fischman, Marian W ; Elkashef, Ahmed ; Herman, Barbara H ; Al-Ghananeem, Abeer M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_2193456573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Chromatography</topic><topic>Drug abuse</topic><topic>Drug addiction</topic><topic>Drugs</topic><topic>Mass spectrometry</topic><topic>Medical research</topic><topic>Narcotics</topic><topic>Pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yu, Elmer</creatorcontrib><creatorcontrib>Miotto, Karen</creatorcontrib><creatorcontrib>Akerele, Evaristo</creatorcontrib><creatorcontrib>O'Brien, Charles P</creatorcontrib><creatorcontrib>Ling, Walter</creatorcontrib><creatorcontrib>Kleber, Herbert</creatorcontrib><creatorcontrib>Fischman, Marian W</creatorcontrib><creatorcontrib>Elkashef, Ahmed</creatorcontrib><creatorcontrib>Herman, Barbara H</creatorcontrib><creatorcontrib>Al-Ghananeem, Abeer M</creatorcontrib><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><collection>Social Services Abstracts</collection><collection>Sociological Abstracts</collection><collection>ProQuest Criminal Justice (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><jtitle>The American journal of drug and alcohol abuse</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yu, Elmer</au><au>Miotto, Karen</au><au>Akerele, Evaristo</au><au>O'Brien, Charles P</au><au>Ling, Walter</au><au>Kleber, Herbert</au><au>Fischman, Marian W</au><au>Elkashef, Ahmed</au><au>Herman, Barbara H</au><au>Al-Ghananeem, Abeer M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Pharmacokinetics of Lofexidine, the [alpha] 2-Adrenergic Receptor Agonist, in Opiate Addicts Plasma Using a Highly Sensitive Liquid Chromatography Tandem Mass Spectrometric Analysis</atitle><jtitle>The American journal of drug and alcohol abuse</jtitle><date>2008-09-01</date><risdate>2008</risdate><volume>34</volume><issue>5</issue><spage>611</spage><pages>611-</pages><issn>0095-2990</issn><eissn>1097-9891</eissn><coden>AJDABD</coden><abstract>The objective of this investigation was to characterize the pharmacokinetic profile of lofexidine. Lofexidine is an orally bioavailable α 2-adrenergic receptor agonist analogue of clonidine that acts centrally to suppress opiate withdrawal symptoms. During the detoxification period of a phase 3 placebo-controlled, randomized, double-blind trial, six subjects were entered in this preliminary pharmacokinetic study. Pharmacokinetic analysis of plasma samples collected during study day 7 indicated that C... was 3242 ± 917 ng/L. The mean trough levels between the study days were not significantly different (p &gt; .05), suggesting that the subjects were at steady-state. Although preliminary due to the limited number of subjects, these findings are the first to document lofexidine clinical pharmacokinetics in opiate addicts using a highly sensitive liquid chromatography tandem mass spectrometric analysis. (ProQuest: ... denotes formulae/symbols omitted.)</abstract><cop>New York</cop><pub>Taylor &amp; Francis Ltd</pub><doi>10.1080/00952990802308122</doi></addata></record>
fulltext fulltext
identifier ISSN: 0095-2990
ispartof The American journal of drug and alcohol abuse, 2008-09, Vol.34 (5), p.611
issn 0095-2990
1097-9891
language eng
recordid cdi_proquest_journals_219345657
source Applied Social Sciences Index & Abstracts (ASSIA); Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list); Sociological Abstracts; SPORTDiscus with Full Text
subjects Chromatography
Drug abuse
Drug addiction
Drugs
Mass spectrometry
Medical research
Narcotics
Pharmacology
title Clinical Pharmacokinetics of Lofexidine, the [alpha] 2-Adrenergic Receptor Agonist, in Opiate Addicts Plasma Using a Highly Sensitive Liquid Chromatography Tandem Mass Spectrometric Analysis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T15%3A21%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Pharmacokinetics%20of%20Lofexidine,%20the%20%5Balpha%5D%202-Adrenergic%20Receptor%20Agonist,%20in%20Opiate%20Addicts%20Plasma%20Using%20a%20Highly%20Sensitive%20Liquid%20Chromatography%20Tandem%20Mass%20Spectrometric%20Analysis&rft.jtitle=The%20American%20journal%20of%20drug%20and%20alcohol%20abuse&rft.au=Yu,%20Elmer&rft.date=2008-09-01&rft.volume=34&rft.issue=5&rft.spage=611&rft.pages=611-&rft.issn=0095-2990&rft.eissn=1097-9891&rft.coden=AJDABD&rft_id=info:doi/10.1080/00952990802308122&rft_dat=%3Cproquest%3E1589444861%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_journals_2193456573%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=219345657&rft_id=info:pmid/&rfr_iscdi=true